Haleon PLC Sponsored ADR (HLN)
(Delayed Data from NYSE)
$8.46 USD
+0.13 (1.56%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $8.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HLN 8.46 +0.13(1.56%)
Will HLN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HLN
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
HLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
Other News for HLN
Notable Two Hundred Day Moving Average Cross - HLN
LONDON MARKET CLOSE: CAC 40 underperforms amid political uncertainty
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
Dr. Reddy's to acquire Haleon's global portfolio of brands in the NRT category